

Pediatric Medical Group, Inc. (MD)

NYSE; healthcare; SIC 8060, Services-Hospitals; CIK 0000893949

Pediatric Medical Group, Inc.	
MD; healthcare	
Grade	C A B C D E middle fifth of 371 graded peers percentile 46.2; sampling error 2.5 points; lower is stronger
Rank	172 of 371
Profitability	C percentile 47.0
Solvency	C percentile 47.8
Growth and financing	C percentile 44.6
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$2.2B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress
Inputs computable	8 of 14
Graded from	filings received through Feb 19, 2026 232 days before the rescans; latest periodic filing 10-Q received Aug 4, 2026
Last close	\$26.27 2026-10-08; market equity \$2.1B
Price used in grade	None



C, the tortoise

middle fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans


split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: D/E from Feb 21, 2022, D from Feb 21, 2023, B/C from Feb 21, 2026, C from Mar 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 19, 2026

"Geographic Coverage." Adverse changes or conditions affecting these particular states, such as healthcare reforms, changes in laws and regulations, increases in unreimbursed services arising from services furnished to undocumented noncitizens, reduced Medicaid eligibility or reimbursements and government investigations, economic conditions, weather conditions, and natural disasters may have an adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 47.0						
Gross profitability		not computable	32.2%			one or more required annual facts are missing
Return on invested capital		14.6%	9.3%	31.5	74	2025-12-31
Accruals ratio		(4.8%)	(6.6%)	62.5	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 47.8						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		2.05	(0.31)	28.6	756	2025-12-31
Net debt to EBITDA		0.85x	1.82x	37.8	75	2025-12-31
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		1.66x	2.96x	77.1	839	2025-12-31
Growth and financing, sleeve percentile 44.6						
Revenue growth, three-year compound		(1.0%)	10.0%	73.7	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 0
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		(1.5%)	2.1%	54.6	704	2025-12-31
Net share issuance, one year		(3.3%)	2.5%	5.4	634	2026-02-13

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
167	Johnson & Johnson (JNJ)	44.9	C	
168	Lensar, Inc. (LNSR)	45.1	C	
169	Integer Holdings Corp. (ITGR)	45.4	C	
170	Zimmer Biomet Holdings, Inc. (ZBH)	45.7	C	
171	Orasure Technologies Inc. (OSUR)	45.9	C	
172	Pediatrix Medical Group, Inc. (MD) <	46.2	C	
173	Enovis Corp. (ENOV)	46.5	C	
174	Align Technology Inc. (ALGN)	46.8	C	
175	ClearPoint Neuro, Inc. (CLPT)	47.0	C	
176	Anika Therapeutics, Inc. (ANIK)	47.3	C	fortress balance sheet
177	Davita Inc. (DVA)	47.6	C	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	56.6%	8.0%	79
Distance from 52-week high	(4.2%)	(31.4%)	94
EBIT to enterprise value	9.3%	(1.5%)	90
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.41	0.28	63
Sales to price	0.90	0.31	80
Composite equity issuance, five years	(5.2%)	20.3%	19
Relative strength against the sector, log excess return	0.24	(0.14)	79

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$288.9M
Operating cash flow, four quarters	\$246.9M
Months of runway	not finite
Days since last periodic filing	66 (10-Q received Aug 4, 2026)
Median daily dollar volume, 63 sessions	\$18.2M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	\$208.8M	2025-12-31	2026-02-19	10-K	0001193125-26-058074
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$216.4M	2025-12-31	2026-02-19	10-K	0001193125-26-058074
3	income tax	us-gaap:IncomeTaxExpenseBenefit	\$51.0M	2025-12-31	2026-02-19	10-K	0001193125-26-058074
4	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	\$570.5M	2025-12-31	2026-02-19	10-K	0001193125-26-058074
5	book equity	us-gaap:StockholdersEquity	\$865.9M	2025-12-31	2026-02-19	10-K	0001193125-26-058074
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$375.2M	2025-12-31	2026-02-19	10-K	0001193125-26-058074
7	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	\$597.1M	2024-12-31	2026-02-19	10-K	0001193125-26-058074
8	book equity	us-gaap:StockholdersEquity	\$764.9M	2024-12-31	2026-02-19	10-K	0001193125-26-058074
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$229.9M	2024-12-31	2026-02-19	10-K	0001193125-26-058074
10	net income	us-gaap:NetIncomeLoss	\$165.4M	2025-12-31	2026-02-19	10-K	0001193125-26-058074
11	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$271.1M	2025-12-31	2026-02-19	10-K	0001193125-26-058074
12	assets	us-gaap:Assets	\$2.2B	2025-12-31	2026-02-19	10-K	0001193125-26-058074
13	assets	us-gaap:Assets	\$2.2B	2024-12-31	2026-02-19	10-K	0001193125-26-058074
14	current assets	us-gaap:AssetsCurrent	\$763.5M	2025-12-31	2026-02-19	10-K	0001193125-26-058074
15	current liabilities	us-gaap:LiabilitiesCurrent	\$458.9M	2025-12-31	2026-02-19	10-K	0001193125-26-058074
16	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$83.2M	2025-12-31	2026-02-19	10-K	0001193125-26-058074
17	liabilities	us-gaap:Liabilities	\$1.4B	2025-12-31	2026-02-19	10-K	0001193125-26-058074
18	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$21.8M	2025-12-31	2026-02-19	10-K	0001193125-26-058074
19	operating income	us-gaap:OperatingIncomeLoss	\$7.3M	2023-12-31	2026-02-19	10-K	0001193125-26-058074
20	interest expense	us-gaap:InterestExpense	\$42.1M	2023-12-31	2024-02-20	10-K	0000950170-24-016794
21	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$1.9B	2025-12-31	2026-02-19	10-K	0001193125-26-058074
22	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$2.0B	2024-12-31	2026-02-19	10-K	0001193125-26-058074
23	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$2.0B	2023-12-31	2026-02-19	10-K	0001193125-26-058074
24	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$2.0B	2022-12-31	2025-02-20	10-K	0000950170-25-023730
25	assets	us-gaap:Assets	\$2.2B	2023-12-31	2025-02-20	10-K	0000950170-25-023730
26	assets	us-gaap:Assets	\$2.3B	2022-12-31	2024-02-20	10-K	0000950170-24-016794
27	shares outstanding	dei:EntityCommonStockSharesOutstanding	83,001,072	2026-02-13	2026-02-19	10-K	0001193125-26-058074
28	shares outstanding	dei:EntityCommonStockSharesOutstanding	85,829,575	2025-02-14	2025-02-20	10-K	0000950170-25-023730